Koji Hasegawa Selected Research

GATA4 Transcription Factor

1/2022	Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response.
12/2016	Regulation of Cardiac Transcription Factor GATA4 by Post-Translational Modification in Cardiomyocyte Hypertrophy and Heart Failure.
3/2002	Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Koji Hasegawa Research Topics

Disease

49	Heart Failure 11/2022 - 01/2002
26	Hypertrophy 06/2022 - 03/2002
17	Myocardial Infarction 01/2022 - 07/2002
16	Atrial Fibrillation 01/2022 - 01/2014
16	Cardiomegaly (Heart Hypertrophy) 01/2022 - 01/2004
14	Stroke (Strokes) 01/2022 - 05/2005
13	Atherosclerosis 04/2022 - 07/2010
10	Coronary Artery Disease (Coronary Atherosclerosis) 11/2022 - 01/2014
10	Inflammation (Inflammations) 02/2020 - 02/2007
9	Fibrosis (Cirrhosis) 01/2022 - 01/2011
8	Obesity 01/2022 - 05/2007
8	Hemorrhage 11/2021 - 12/2016
8	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 06/2008
7	Embolism (Embolus) 11/2021 - 01/2015
7	Weight Gain 12/2019 - 01/2013
6	Heart Diseases (Heart Disease) 02/2020 - 01/2004
5	Type 2 Diabetes Mellitus (MODY) 01/2022 - 07/2016
5	Hypertension (High Blood Pressure) 07/2021 - 04/2010
5	Neoplasms (Cancer) 03/2021 - 03/2004
5	Insulin Resistance 01/2020 - 11/2008
5	Atherosclerotic Plaque (Atheroma) 01/2019 - 01/2011
5	Dyslipidemias (Dyslipidemia) 01/2015 - 01/2011
4	Ischemic Stroke 08/2021 - 10/2018
3	Chronic Renal Insufficiency 01/2022 - 12/2017
3	Diabetes Mellitus 06/2020 - 08/2016
3	COVID-19 02/2020 - 02/2020
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 06/2008
3	Body Weight (Weight, Body) 01/2020 - 02/2012
3	Abdominal Obesity 04/2019 - 11/2016
3	Ventricular Remodeling 01/2014 - 01/2002
2	Cardiotoxicity 01/2022 - 09/2010
2	Left Ventricular Dysfunction 11/2021 - 01/2015
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 07/2021 - 02/2021
2	Myocarditis (Carditis) 02/2020 - 09/2005
2	Glucose Intolerance 01/2019 - 01/2010
2	Hypercholesterolemia 12/2016 - 01/2011
2	Hypersensitivity (Allergy) 07/2016 - 09/2005

Drug/Important Bio-Agent (IBA)

15	CurcuminIBA 06/2022 - 03/2008
13	AnticoagulantsIBA 01/2022 - 10/2009
11	Proteins (Proteins, Gene)FDA Link 04/2022 - 05/2003
11	oxidized low density lipoproteinIBA 01/2019 - 06/2008
10	Histone Acetyltransferases (Histone Acetyltransferase)IBA 06/2022 - 02/2006
9	Transcription Factors (Transcription Factor)IBA 12/2016 - 05/2003
7	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 06/2022 - 09/2004
7	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2010
6	Pharmaceutical PreparationsIBA 01/2022 - 09/2010
6	LipidsIBA 01/2020 - 01/2011
6	CholesterolIBA 01/2019 - 01/2011
5	Biological ProductsIBA 02/2021 - 06/2003
4	AdipokinesIBA 04/2022 - 11/2008
4	Histones (Histone)IBA 01/2022 - 01/2020
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 03/2004
4	Eicosapentaenoic AcidIBA 01/2022 - 12/2012
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2015
4	Messenger RNA (mRNA)IBA 01/2022 - 04/2010
4	Hemoglobins (Hemoglobin)IBA 11/2020 - 10/2009
4	Triglycerides (Triacylglycerol)IBA 01/2020 - 01/2011
4	LDL CholesterolIBA 01/2019 - 06/2008
4	MicroRNAs (MicroRNA)IBA 10/2018 - 08/2009
4	HDL CholesterolIBA 11/2017 - 01/2011
4	Lipoproteins (Lipoprotein)IBA 11/2016 - 06/2008
4	Insulin (Novolin)FDA Link 07/2016 - 10/2006
4	LDL Lipoproteins (beta Lipoproteins)IBA 01/2016 - 06/2008
3	GATA4 Transcription FactorIBA 01/2022 - 03/2002
3	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2022 - 01/2014
3	SaltsIBA 07/2021 - 03/2008
3	Indicators and Reagents (Reagents)IBA 01/2021 - 06/2008
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 01/2015
3	Vascular Endothelial Growth Factor CIBA 01/2020 - 01/2011
3	Warfarin (Coumadin)FDA LinkGeneric 08/2017 - 04/2013
3	DNA (Deoxyribonucleic Acid)IBA 04/2008 - 02/2006
3	Endothelin-1 (Endothelin 1)IBA 11/2004 - 03/2002
2	omega-Chloroacetophenone (Mace)IBA 01/2022 - 08/2021
2	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2020
2	Docosahexaenoic AcidsIBA 01/2022 - 01/2014
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 12/2021 - 11/2018
2	zerumboneIBA 11/2021 - 02/2021
2	TeaIBA 11/2021 - 01/2020
2	Atrial Natriuretic Factor (ANF)IBA 11/2021 - 01/2002
2	Metformin (Glucophage)FDA LinkGeneric 10/2021 - 06/2020
2	pitavastatin (itavastatin)FDA Link 01/2021 - 12/2016
2	Rosuvastatin Calcium (Crestor)FDA Link 01/2021 - 12/2016
2	PolyphenolsIBA 11/2020 - 01/2018
2	Mitogen-Activated Protein Kinase 3IBA 11/2020 - 03/2002
2	Hypoglycemic Agents (Hypoglycemics)IBA 06/2020 - 01/2010
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 02/2020 - 01/2011
2	AcetyltransferasesIBA 01/2020 - 02/2006
2	1,5- bis(3,5- bis(methoxymethoxy)phenyl)penta- 1,4- dien- 3- oneIBA 01/2020 - 12/2017
2	Nicotine FDA Link 04/2019 - 01/2013
2	ApolipoproteinsIBA 01/2019 - 10/2018
2	Syntex adjuvant formulationIBA 10/2018 - 12/2017
2	AdiponectinIBA 01/2018 - 06/2008
2	LectinsIBA 01/2018 - 07/2010
2	CytokinesIBA 05/2017 - 09/2005
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 08/2016 - 07/2016

Therapy/Procedure

30	Therapeutics 11/2022 - 05/2007
5	Drug Therapy (Chemotherapy) 03/2021 - 09/2010
3	Vena Cava Filters (Inferior Vena Cava Filter) 07/2016 - 10/2009
2	Catheter Ablation 08/2021 - 12/2018
2	Ligation 12/2019 - 01/2003